Sanofi's Q3 profit exceeded expectations driven by Dupixent sales, despite lower vaccination rates due to negative perceptions around vaccines. The company's overall performance was strong, with shares rising by 2%. Sanofi remains optimistic about future growth and maintains its forecast for sales and earnings growth this year.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing